EcoR1 Capital
EcoR1 Capital is a biotech-focused investment advisory firm.
Business Model:
Revenue: $5.9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed EcoR1 Capital Information
Geographic Data
Address: 409 Illinois St
City: San Francisco
State: CA
Zip: 94158
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$355M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
EcoR1 Capital is an investment advisory firm that focused on fundamental biotechnology companies.
Contact Phone:
+14157543517
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 10/2018 | Avidity Biosciences | Series B | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 4/2018 | Magenta Therapeutics | Series C | 0 |
| 4/2020 | Accent Therapeutics | Series B | 0 |
| 3/2019 | Ashvattha Therapeutics | Series A | 7M |
| 1/2022 | Eikon Therapeutics | Series B | 0 |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 1/2014 | Atara Biotherapeutics | Series B | 13.5M |
| 11/2019 | Pieris Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2015 | Kura Oncology | Private Equity Round | 60M |
| 5/2019 | ElevateBio | Series A | 150M |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 1/2018 | Scholar Rock | Series C | 47M |
| 8/2017 | aTyr Pharma | Post-IPO Equity | 45M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 7/2020 | Alpine Immune Sciences | Post-IPO Equity | 60M |
| 3/2020 | ElevateBio | Series B | 170M |
| 3/2018 | UNITY Biotechnology | Series C | 55M |
| 9/2018 | Atreca | Series C | 125M |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 12/2020 | Syros Pharmaceuticals | Post-IPO Equity | 90.5M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 12/2015 | ORIC Pharmaceuticals | Series B | 53M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 9/2020 | Dewpoint Therapeutics | Series B | 0 |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 8/2020 | Freenome | Series C | 270M |
| 12/2014 | Naurex | Series C | 0 |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 9/2015 | Intellia Therapeutics | Series B | 0 |
| 6/2021 | Ajax Therapeutics | Venture Round | 0 |
| 6/2023 | ORIC Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2015 | Clementia Pharmaceuticals | Venture Round | 0 |
| 9/2014 | Scholar Rock | Series A | 20M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 5/2021 | Corvus Pharmaceuticals | Post-IPO Equity | 10M |
| 6/2015 | Kezar Life Sciences | Series A | 23M |
| 4/2021 | Tectonic Therapeutic | Series A | 80M |
| 5/2018 | Accent Therapeutics | Series A | 40M |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 12/2013 | Atara Biotherapeutics | Series B | 38.5M |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 3/2014 | SAGE Therapeutics | Series C | 38M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 6/2020 | Shattuck Labs | Series B | 0 |
| 5/2019 | AlloVir | Series B | 120M |
| 2/2019 | Neurogene | Series A | 68.5M |
| 2/2021 | Notch Therapeutics | Series A | 85M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 3/2018 | Omniox | Series D | - |
| 4/2021 | Janux Therapeutics | Series B | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 3/2021 | Aktis Oncology | Series A | 72M |
| 8/2015 | Metacrine | Series A | 36M |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 2/2022 | Dewpoint Therapeutics | Series C | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 3/2021 | ElevateBio | Series C | 525M |
| 6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
| 5/2023 | ElevateBio | Series D | 0 |
| 7/2022 | AlloVir | Post-IPO Equity | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 3/2020 | Akouos | Series B | 105M |
| 9/2020 | Neogene Therapeutics | Series A | 110M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 9/2014 | Flex Pharma | Venture Round | 0 |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 11/2022 | Abeona Therapeutics | Post-IPO Equity | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 10/2020 | Cellares | Series A | 18M |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 5/2020 | Surface Oncology | Post-IPO Equity | 28.9M |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 7/2022 | AlloVir | Post-IPO Equity | 0 |
| 7/2022 | Gossamer Bio | Post-IPO Equity | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | 2seventy bio | Post-IPO Equity | 0 |
| 2/2022 | Dewpoint Therapeutics | Series C | 0 |
| 1/2022 | Eikon Therapeutics | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
